查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2082056

藥品安全監測市場：2026-2032年全球市場預測（按組件、類型、產品生命週期、給藥方式、製程流程、應用、最終用戶和部署模式分類）

Pharmacovigilance Market by Component, Type, Product Life Cycle, Delivery Mode, Process Flow, Application, End-user, Deployment Model - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥品安全監測市場將成長至 341.7 億美元，複合年成長率為 16.34%。

主要市場統計數據
基準年 2025 118.4億美元
預計年份：2026年 137.1億美元
預測年份 2032 341.7億美元
複合年成長率 (%) 16.34%

藥物安全監測市場概覽

藥物安全監測已從單純的後勤部門合規職能發展成為一項策略職能，旨在保護病患、維護產品價值並履行全球藥物安全義務。隨著監管機構對不利事件報告、風險管理計畫、定期獲益風險評估報告和上市後監測的要求不斷提高，生命科學公司正優先考慮快速病例接收、增強訊號檢測能力和建立可審計的安全管治。

藥物安全監測環境的變革性變化

藥物安全監測領域正經歷變革，這體現在監管協調、安全營運數位化以及向積極主動的獲益-風險管理模式的轉變。 ICH E2B (R3)、MedDRA編碼、歐盟良好警戒規範 (GVP)、FDA上市後報告要求以及WHO安全監測原則等標準，正在促進全球安全系統之間更結構化、互通性且可追溯的安全資料的交換。

人工智慧對藥物安全性的累積影響

人工智慧透過提高常規工作流程的速度、一致性和可追溯性，對藥物安全監測整體產生了累積影響。自然語言處理、基於機器學習的分類、實體提取、重複檢測、自動說明生成、智慧MedDRA編碼和文獻篩檢等技術，在經過檢驗的規則和人工監督下實施，可以減輕病例登記、分診和品管方面的人工負擔。

關於藥物安全監測的關鍵區域見解

隨著中國、印度、日本、韓國、澳洲和東協等市場臨床開發、學名藥和生物相似藥生產以及國家不利事件通報系統的擴展，亞太地區的重要性日益凸顯。該地區的監管機構提高了對本地病例報告、風險管理和上市後安全性監測的要求，使得區域藥物警戒協調對於使用不同語言、格式和時間表的申辦方至關重要。北美仍然是藥物警戒創新的成熟中心，這得益於美國食品藥品監督管理局（FDA）的不良事件報告系統（FAERS）、哨兵舉措（Sentinel Initiative）、風險評估和緩解策略（REMS）監管、加拿大衛生署的報告要求、廣泛的臨床研究活動以及完善的生命外包科學基礎設施。

來自東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約等主要組織的見解。

在東協市場，區域相互依存、本地安全報告、藥物安全監測能力發展以及監管機構間的合作日益密切，這使得該區域集團對於尋求擴充性的亞太安全模式的企業至關重要。在海灣合作理事會（GCC）內部，透過監管機構間的協調、醫院報告系統、國家衛生戰略以及對數位醫療的投資，藥物安全監測正在海灣各國推進，從而產生更系統化的安全數據，用於上市後監測。

主要國家全球藥物安全監測趨勢

美國透過FDA的FAERS、Sentinel和REMS監測與報告要求，以及成熟的製藥公司和安全服務供應商生態系統，在上市後大規模監測方面主導。加拿大透過加拿大衛生署及其不利事件報告框架，維持嚴格的藥物安全監測要求。同時，墨西哥和巴西仍然是拉丁美洲的重要市場，墨西哥聯邦衛生風險防護委員會（COFEPRIS）和巴西國家衛生監督局（ANVISA）正在持續推進藥物安全監測和監管的現代化，並加強當地的報告機制。

針對負責藥物安全監測人員的實用建議

產業領導者應優先考慮基於風險的藥物安全監測營運模式，該模式應連接全球安全資料庫、本地子公司流程、醫學審查、品管、訊號檢測和監管資訊。投資建立一個支援ICH E2B (R3) 的互通平台，該平台具備標準化的MedDRA編碼、自動病例路由、文獻篩檢、重複檢測、審計追蹤和合規提交功能，可以縮短週期時間，同時提高數據品質並加強對檢查的準備。

調查方法

本執行摘要是根據公開監管指南、國際安全標準、國家藥品安全監測框架和既定行業慣例的二手資料研究。主要參考資料包括美國食品藥物管理局 (FDA) 的上市後安全體系、歐洲藥品管理局 (EMA) 和歐盟的藥品良好規範 (GVP) 要求、世界衛生組織 (WHO) 的藥品安全監測原則、國際人用藥品註冊技術協調會 (ICH) 的安全資料標準、MedDRA 術語使用規範以及各國監管機構的指南。

結論

藥物安全監測正邁向資料密集、智慧主導的時代，速度、準確性、互通性和透明度是決定營運優勢的關鍵因素。建構了現代化安全架構的機構將更有能力應對全球報告的複雜性，更早發現新出現的風險，支持合規的風險效益決策，並維護與監管機構、臨床醫生和患者的信任。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：藥品安全監測市場：依組件分類

  • 軟體
  • 服務

第8章：藥品安全監測市場：按類型分類

  • 佇列事件監測
  • 電子健康記錄挖掘
  • 加強不利事件報告
  • 自願報告
  • 有針對性的自願報告

第9章：藥品安全監測市場：依產品生命週期分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段
  • 臨床前

第10章：藥品安全監測市場：以交付方式分類

  • 內部
  • 外包

第11章：藥品安全監測市場：依流程分類

  • 案例資料管理
    • 案例數據分析
    • 病例記錄
    • 醫學審查和報告
  • 風險管理系統
    • 風險評估系統
    • 風險緩解系統
  • 訊號檢測
    • 不利事件分析
    • 不利事件記錄
    • 不利事件的審查和報告

第12章：藥品安全監測市場：依應用領域分類

  • 心血管系統
  • 感染疾病
  • 神經病學
  • 腫瘤學
  • 呼吸系統

第13章：藥品安全監測市場：依最終用戶分類

  • 生技公司
  • 醫療設備製造商
  • 製藥

第14章：藥品安全監測市場：依部署模式分類

  • 現場
  • 基於雲端的
  • 混合

第15章：藥品安全監測市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章：藥品安全監測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：藥品安全監測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi SA
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited
Product Code: MRR-43676CF420A3

The Pharmacovigilance Market is projected to grow by USD 34.17 billion at a CAGR of 16.34% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.84 billion
Estimated Year [2026] USD 13.71 billion
Forecast Year [2032] USD 34.17 billion
CAGR (%) 16.34%

Pharmacovigilance Market Introduction

Pharmacovigilance has moved from a back-office compliance function to a strategic capability for protecting patients, preserving product value, and meeting global drug safety obligations. As regulators expand expectations for adverse event reporting, risk management plans, periodic benefit-risk evaluation reports, and post-marketing surveillance, life sciences organizations are prioritizing faster case intake, stronger signal detection, and auditable safety governance.

The pharmacovigilance landscape is shaped by rising medicine utilization, complex biologics and vaccines, expanding clinical trial activity, and larger volumes of real-world safety data from electronic health records, claims, patient support programs, call centers, literature, social media, and digital health channels. Organizations that can convert these data streams into validated individual case safety reports, risk signals, and compliant regulatory submissions are better positioned to maintain inspection readiness, strengthen benefit-risk management, and improve patient outcomes.

Transformative Shifts in the Pharmacovigilance Landscape

The pharmacovigilance landscape is being transformed by regulatory harmonization, digitized safety operations, and a shift toward proactive benefit-risk management. Standards such as ICH E2B(R3), MedDRA coding, EU Good Pharmacovigilance Practices, FDA post-market reporting expectations, and WHO safety monitoring principles are encouraging more structured, interoperable, and traceable safety data exchange across global safety systems.

At the same time, safety teams are absorbing higher reporting volumes from specialty drugs, biologics, vaccines, combination products, social listening programs, digital therapeutics, telehealth, and patient engagement platforms. This is pushing sponsors and service providers to redesign operating models around automation, quality-by-design, global case processing hubs, local affiliate oversight, medical safety review, and integrated signal management to support timely regulatory compliance and patient safety decisions.

Cumulative Impact of Artificial Intelligence on Drug Safety

Artificial intelligence is having a cumulative impact across pharmacovigilance by improving the speed, consistency, and traceability of routine workflows. Natural language processing, machine learning classification, entity extraction, duplicate detection, automated narrative drafting, intelligent MedDRA coding, and literature screening can reduce manual effort in case intake, triage, and quality control when implemented with validated rules and human oversight.

The strongest use cases are emerging where AI supports, rather than replaces, qualified safety professionals. Regulators continue to expect explainability, audit trails, documented validation, data privacy safeguards, and medical judgment for causality assessment, seriousness evaluation, expectedness review, and signal detection. As a result, AI adoption is most effective when embedded in governed safety systems that align with GxP quality standards, risk-based validation, cybersecurity controls, and transparent change management.

Key Regional Insights for Pharmacovigilance

Asia-Pacific is gaining importance as China, India, Japan, South Korea, Australia, and ASEAN markets expand clinical development, generic and biosimilar manufacturing, and national adverse event reporting systems. Regulatory authorities across the region are increasing expectations for local case reporting, risk management, and post-authorization safety monitoring, making regional pharmacovigilance coordination critical for sponsors operating across diverse languages, formats, and timelines. North America remains a mature center for pharmacovigilance innovation, supported by FDA FAERS, the Sentinel Initiative, REMS oversight, Health Canada reporting requirements, extensive clinical research activity, and established life sciences outsourcing capacity.

Latin America is strengthening post-marketing surveillance as Brazil, Mexico, and other markets modernize regulatory procedures and increase local safety reporting expectations. Europe continues to set a high bar through the European Medicines Agency, EudraVigilance, EU Good Pharmacovigilance Practices, formal risk management planning, and periodic safety reporting obligations. The Middle East is advancing national pharmacovigilance centers, electronic reporting, and local safety responsibilities as healthcare systems digitalize, while Africa is building medicine safety capacity through national regulatory authorities, WHO program participation, adverse event monitoring for vaccines and essential medicines, and stronger reliance-based regulatory collaboration as medicine access expands.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly aligned around regional reliance, local safety reporting, pharmacovigilance capacity building, and regulatory cooperation, making the bloc important for companies seeking scalable Asia-Pacific safety models. The GCC is advancing medicine safety oversight across Gulf states through regulatory coordination, hospital reporting systems, national health strategies, and digital health investments that generate more structured safety data for post-marketing surveillance.

The European Union remains the global benchmark for rigorous pharmacovigilance governance through centralized procedures, EudraVigilance, legally defined responsibilities for marketing authorization holders, qualified person requirements, and EU Good Pharmacovigilance Practices. BRICS countries represent strategically important demand because of large patient populations, domestic pharmaceutical manufacturing, expanding clinical research participation, and maturing surveillance systems. G7 markets continue to shape advanced standards for data integrity, inspection readiness, AI governance, real-world evidence, and benefit-risk transparency, while NATO countries add relevance through health security, medical countermeasure monitoring, supply resilience, and safety surveillance for critical medicines used in emergency preparedness.

Key Country Insights in Global Pharmacovigilance

The United States leads in large-scale post-market surveillance through FDA FAERS, Sentinel, REMS oversight, mandatory reporting obligations, and a mature ecosystem of pharmaceutical sponsors and safety service providers. Canada maintains strong pharmacovigilance requirements through Health Canada and its adverse reaction reporting framework, while Mexico and Brazil are important Latin American markets as COFEPRIS and ANVISA continue to strengthen medicine safety oversight, regulatory modernization, and local reporting practices.

In Europe, the United Kingdom, Germany, France, Italy, and Spain remain central to clinical development, regulatory science, medical literature monitoring, and EU-aligned safety operations, with the United Kingdom operating through the MHRA and Yellow Card Scheme and EU members contributing to EudraVigilance-based surveillance. Russia requires localized regulatory attention due to national reporting expectations and local regulatory procedures. China and India are critical because of their scale in clinical research, manufacturing, pharmacovigilance program development, and patient populations; Japan and South Korea combine advanced regulatory systems with high adoption of structured safety data standards and strong post-marketing obligations; and Australia offers a mature, transparent system under the Therapeutic Goods Administration that supports regional pharmacovigilance planning across Asia-Pacific.

Actionable Recommendations for Pharmacovigilance Leaders

Industry leaders should prioritize a risk-based pharmacovigilance operating model that connects global safety databases, local affiliate processes, medical review, quality management, signal detection, and regulatory intelligence. Investing in interoperable platforms that support ICH E2B(R3), standardized MedDRA coding, automated case routing, literature screening, duplicate detection, audit trails, and compliant submissions can reduce cycle times while improving data quality and inspection readiness.

Organizations should also establish AI governance before scaling automation. Practical actions include validating algorithms, documenting model performance, preserving human medical oversight, monitoring bias, integrating privacy controls, maintaining vendor oversight, and training safety teams to work with intelligent workflow tools. Vendor partnerships should be assessed on inspection history, pharmacovigilance domain expertise, data security, multilingual coverage, regulatory submission capability, business continuity, and measurable quality outcomes.

Research Methodology

This executive summary is based on secondary research from publicly available regulatory guidance, international safety standards, national pharmacovigilance frameworks, and established industry practices. Core reference points include FDA post-marketing safety systems, EMA and EU GVP requirements, WHO pharmacovigilance principles, ICH safety data standards, MedDRA terminology practices, and country-level regulatory authority guidance.

The analysis applies a qualitative market intelligence approach, evaluating regulatory maturity, adverse event reporting infrastructure, technology adoption, outsourcing trends, clinical development activity, safety database interoperability, inspection expectations, and regional policy direction. Insights were synthesized to support strategic decision-making for pharmaceutical manufacturers, biotechnology companies, contract research organizations, pharmacovigilance service providers, medical affairs teams, and digital safety platform vendors without applying market sizing, market share, or forecast assumptions.

Conclusion

Pharmacovigilance is entering a more data-intensive and intelligence-led era in which speed, accuracy, interoperability, and transparency define operational advantage. Organizations that build modern safety architectures will be better prepared to manage global reporting complexity, detect emerging risks earlier, support compliant benefit-risk decisions, and maintain trusted relationships with regulators, clinicians, and patients.

As AI, real-world evidence, structured data standards, and harmonized regulatory expectations continue to mature, pharmacovigilance will increasingly support enterprise-wide benefit-risk strategy rather than isolated compliance tasks. Leaders that combine technology with medical expertise, quality discipline, validated governance, and regional regulatory intelligence can create resilient safety systems for the next generation of medicines.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pharmacovigilance Market, by Component

  • 7.1. Software
  • 7.2. Services

8. Pharmacovigilance Market, by Type

  • 8.1. Cohort Event Monitoring
  • 8.2. EHR Mining
  • 8.3. Intensified ADR Reporting
  • 8.4. Spontaneous Reporting
  • 8.5. Targeted Spontaneous Reporting

9. Pharmacovigilance Market, by Product Life Cycle

  • 9.1. Phase I
  • 9.2. Phase II
  • 9.3. Phase III
  • 9.4. Phase IV
  • 9.5. Pre-clinical

10. Pharmacovigilance Market, by Delivery Mode

  • 10.1. In-house
  • 10.2. Outsourced

11. Pharmacovigilance Market, by Process Flow

  • 11.1. Case Data Management
    • 11.1.1. Case Data Analysis
    • 11.1.2. Case Logging
    • 11.1.3. Medical Reviewing & Reporting
  • 11.2. Risk Management System
    • 11.2.1. Risk Evaluation System
    • 11.2.2. Risk Mitigation System
  • 11.3. Signal Detection
    • 11.3.1. Adverse Event Analysis
    • 11.3.2. Adverse Event Logging
    • 11.3.3. Adverse Event Review & Reporting

12. Pharmacovigilance Market, by Application

  • 12.1. Cardiovascular
  • 12.2. Infectious Diseases
  • 12.3. Neurology
  • 12.4. Oncology
  • 12.5. Respiratory

13. Pharmacovigilance Market, by End-user

  • 13.1. Biotechnology Companies
  • 13.2. Medical Device Manufacturers
  • 13.3. Pharmaceuticals

14. Pharmacovigilance Market, by Deployment Model

  • 14.1. On-Premises
  • 14.2. Cloud-Based
  • 14.3. Hybrid

15. Pharmacovigilance Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Pharmacovigilance Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Pharmacovigilance Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. Accenture, PLC
  • 19.2. Bristol-Myers Squibb Company
  • 19.3. Capgemini SE
  • 19.4. ClinChoice
  • 19.5. F. Hoffmann-La Roche AG
  • 19.6. GlaxoSmithKline PLC
  • 19.7. HCL Technologies Limited
  • 19.8. ICON PLC
  • 19.9. Infosys Limited
  • 19.10. International Business Machines Corporation
  • 19.11. IQVIA Inc.
  • 19.12. ITclinical
  • 19.13. Linical Co., Ltd.
  • 19.14. Novartis AG
  • 19.15. Oracle Corporation
  • 19.16. Parexel International
  • 19.17. Pfizer Inc.
  • 19.18. Quanticate International limited
  • 19.19. Sanofi S.A.
  • 19.20. Syneos Health
  • 19.21. TAKE Solutions Limited
  • 19.22. TATA Consultancy Services Limited
  • 19.23. Wipro Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACOVIGILANCE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PHARMACOVIGILANCE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PHARMACOVIGILANCE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PHARMACOVIGILANCE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COHORT EVENT MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COHORT EVENT MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COHORT EVENT MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EHR MINING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EHR MINING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EHR MINING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTENSIFIED ADR REPORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTENSIFIED ADR REPORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTENSIFIED ADR REPORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SPONTANEOUS REPORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SPONTANEOUS REPORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SPONTANEOUS REPORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED SPONTANEOUS REPORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED SPONTANEOUS REPORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED SPONTANEOUS REPORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHASE IV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHASE IV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHASE IV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRE-CLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRE-CLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PRE-CLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IN-HOUSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN-HOUSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IN-HOUSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OUTSOURCED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OUTSOURCED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OUTSOURCED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CASE DATA MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CASE DATA MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CASE DATA MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CASE DATA ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CASE DATA ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CASE DATA ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CASE LOGGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CASE LOGGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CASE LOGGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MEDICAL REVIEWING & REPORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MEDICAL REVIEWING & REPORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MEDICAL REVIEWING & REPORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RISK MANAGEMENT SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RISK MANAGEMENT SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RISK MANAGEMENT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RISK EVALUATION SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RISK EVALUATION SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RISK EVALUATION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RISK MITIGATION SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RISK MITIGATION SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RISK MITIGATION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SIGNAL DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SIGNAL DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SIGNAL DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADVERSE EVENT ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ADVERSE EVENT ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADVERSE EVENT ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ADVERSE EVENT LOGGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADVERSE EVENT LOGGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ADVERSE EVENT LOGGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADVERSE EVENT REVIEW & REPORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ADVERSE EVENT REVIEW & REPORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADVERSE EVENT REVIEW & REPORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RESPIRATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RESPIRATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RESPIRATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MEDICAL DEVICE MANUFACTURERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MEDICAL DEVICE MANUFACTURERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MEDICAL DEVICE MANUFACTURERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ON-PREMISES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ON-PREMISES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ON-PREMISES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CLOUD-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CLOUD-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CLOUD-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HYBRID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HYBRID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HYBRID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 204. GCC PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 206. GCC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. GCC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 210. GCC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 211. GCC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 212. GCC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 213. GCC PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. GCC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 215. GCC PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 240. G7 PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 242. G7 PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 244. G7 PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 246. G7 PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 247. G7 PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 248. G7 PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 249. G7 PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. G7 PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 251. G7 PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 252. NATO PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. NATO PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 254. NATO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NATO PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 256. NATO PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 257. NATO PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 258. NATO PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 259. NATO PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 260. NATO PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 261. NATO PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. NATO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 263. NATO PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 277. CANADA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. CANADA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 279. CANADA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. CANADA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 281. CANADA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 282. CANADA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 283. CANADA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 289. MEXICO PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 291. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 293. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 294. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 295. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 296. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 297. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 299. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 300. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 301. BRAZIL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 303. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 305. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 306. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 307. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 308. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 309. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 310. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 311. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 312. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 325. GERMANY PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 327. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 329. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 330. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 331. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 332. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 333. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 337. FRANCE PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 338. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 339. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 341. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 342. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 343. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 344. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 345. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 346. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 347. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 348. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 349. RUSSIA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 350. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 351. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 352. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 353. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 354. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 355. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 356. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 357. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 358. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 359. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 360. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 361. ITALY PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 362. ITALY PHARMACOVIGILANCE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 363. ITALY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 364. ITALY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 365. ITALY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 366. ITALY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 367. ITALY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 368. ITALY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 369. ITALY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)

TABLE